Johnson & Johnson Q2 positive for MedTech – Baird (NYSE:JNJ)

Soon after Johnson & Johnson (NYSE:JNJ) topped expectations with its Q2 2023 results last week, Baird came up with a report indicating brighter days for MedTech, mainly due to accelerating medical procedure volumes and a waning COVID impact in China.

With their MedTech divisions recording double-digit percentage growth, JNJ (JNJ) and its rival medical device maker Abbott Laboratories (ABT) posted better-than-expected Q2 results on Thursday, rallying the subsector.